Genmab — Juni 2024
-
Godmorgen
-
Dagens aktie er Halozyme Therapeutics, Inc..................
Halozyme Therapeutics Inc er en biopharma platformsvirksomhed der forsker i, udvikler og kommercialiserer proprietære enzymer. Terapier fokuseret på humane enzymer
Fokuserer på at udvikle sine proprietære produkter inden for terapeutiske områder med udækkede medicinske behov, med fokus på onkologi, og licensere sin teknologi til biofarmaceutiske virksomheder til i fællesskab at udvikle produkter. https://proinvestor.com/boards/120777 -
-
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference https://proinvestor.com/investornyt/1169144/genmab-to-participate-in-a-fireside-chat-at-the-goldman-sachs-45th-annual-global-healthcare-conference
-
Halozyme Announces Issuance of New European Patent for ENHANZE
Drug Delivery Platform https://markets.ft.com/data/announce/full?dockey=600-202406051605PR_NEWS_USPRX____LA32624-1 -
Tak for info omkring det nye europæiske patent.
-
HALO hæver guidance med $80 mln for 2024. Kan ikke lige gennemskue tallene. Men muligt at JNJ og Genmab skal dele den udgift. https://finance.yahoo.com/news/halozyme-raises-full-2024-financial-123000685.html
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind